跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
G12
首页
药物
G12
G12
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
KRAS MODULATORS AND USES THEREOF
EP 4475956 A1
申请人: QUANTA THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
7 件公开
EP 4680609 A1
申请人: QUANTA THERAPEUTICS INC
优先权: 2023
CN
EP
US
WO
6 件公开
WO 2025049402 A1
申请人: QUANTA THERAPEUTICS INC
优先权: 2023
WO
WO 2025049641 A1
申请人: QUANTA THERAPEUTICS INC
优先权: 2023
WO
WO 2025049619 A1
申请人: QUANTA THERAPEUTICS INC
优先权: 2023
WO
WO 2026112187 A1
申请人: QUANTA THERAPEUTICS INC
优先权: 2024
WO
WO 2026183107 A1
申请人: QUANTA THERAPEUTICS INC
优先权: 2025
WO
TCR MOLECULE TARGETING KRAS G12 MUTATION, AND CELL AND USE THEREOF
EP 4647441 A4
申请人: BEIJING DCTY BIOTECH CO LTD
优先权: 2023
CN
EP
WO
4 件公开
Anti-Rho GTPase conformational single domain antibodies and uses thereof
US 10544210 B2
申请人: INST NAT SANTE RECH MED
优先权: 2015
CN
US
4 件公开
COMPOUND AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME
US 2019372015 A1
申请人: SHANGHAI NICHEM FINE CHEMICAL CO LTD
优先权: 2018
CN
US
4 件公开
COMPOSITIONS AND METHODS FOR KRAS INHIBITION FOR THE TREATMENT OF DISEASE
EP 4669752 A1
申请人: ALTAMIRA THERAPEUTICS AG
优先权: 2023
CN
EP
WO
3 件公开
KRAS INHIBITORS AND USES THEREOF
EP 4771017 A1
申请人: SUZHOU ZANRONG PHARMA LTD
优先权: 2023
CN
EP
WO
3 件公开
WO 2025153038 A1
申请人: SUZHOU ZANRONG PHARMA LTD
优先权: 2024
CN
WO
2 件公开
Pyrimidine based modulators and uses thereof
US 12145947 B2
申请人: QUANTA THERAPEUTICS INC
优先权: 2022
CN
US
3 件公开
WO 2024259169 A1
申请人: QUANTA THERAPEUTICS INC
优先权: 2023
WO
TREATMENT OF FISTULIZING CHROHN'S DISEASE
US 2014050735 A1
申请人: RUEHL ANNE
优先权: 2012
CN
US
2 件公开
POLYPEPTIDE TARGETING KRAS MUTANT PROTEIN AND USE THEREOF, DRUG, AND METHOD
WO 2025218009 A1
申请人: NAT CT NANOSCIENCE & TECHNOLOGY CHINA
优先权: 2024
CN
WO
2 件公开
A MICRONUTRIENT PHARMACEUTICAL COMPOSITION FOR BIOENERGY STIMULATION FOR MAMMAL
EP 4799616 A1
申请人: NASS BOUKELIEN YENTL SUNDARI
优先权: 2025
EP
US
2 件公开
第 1 / 5 页
上一页
下一页
药物
反馈